Cost-benefit of stockpiling drugs for influenza pandemic.
Identifieur interne : 001E42 ( PubMed/Corpus ); précédent : 001E41; suivant : 001E43Cost-benefit of stockpiling drugs for influenza pandemic.
Auteurs : Ran D. Balicer ; Michael Huerta ; Nadav Davidovitch ; Itamar GrottoSource :
- Emerging infectious diseases [ 1080-6040 ] ; 2005.
English descriptors
- KwdEn :
- Acetamides (economics), Acetamides (therapeutic use), Adolescent, Adult, Aged, Antiviral Agents (economics), Antiviral Agents (therapeutic use), Child, Child, Preschool, Cost-Benefit Analysis, Disease Outbreaks (economics), Humans, Infant, Influenza, Human (drug therapy), Influenza, Human (economics), Influenza, Human (epidemiology), Israel (epidemiology), Middle Aged, Models, Biological, Models, Economic, Oseltamivir, World Health Organization.
- MESH :
- chemical , economics : Acetamides, Antiviral Agents.
- chemical , therapeutic use : Acetamides, Antiviral Agents.
- geographic , epidemiology : Israel.
- drug therapy : Influenza, Human.
- economics : Disease Outbreaks, Influenza, Human.
- epidemiology : Influenza, Human.
- Adolescent, Adult, Aged, Child, Child, Preschool, Cost-Benefit Analysis, Humans, Infant, Middle Aged, Models, Biological, Models, Economic, Oseltamivir, World Health Organization.
Abstract
We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.
DOI: 10.3201/eid1108.041156
PubMed: 16102319
Links to Exploration step
pubmed:16102319Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-benefit of stockpiling drugs for influenza pandemic.</title>
<author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D" last="Balicer">Ran D. Balicer</name>
<affiliation><nlm:affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name>
</author>
<author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name>
</author>
<author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16102319</idno>
<idno type="pmid">16102319</idno>
<idno type="doi">10.3201/eid1108.041156</idno>
<idno type="wicri:Area/PubMed/Corpus">001E42</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E42</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-benefit of stockpiling drugs for influenza pandemic.</title>
<author><name sortKey="Balicer, Ran D" sort="Balicer, Ran D" uniqKey="Balicer R" first="Ran D" last="Balicer">Ran D. Balicer</name>
<affiliation><nlm:affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Huerta, Michael" sort="Huerta, Michael" uniqKey="Huerta M" first="Michael" last="Huerta">Michael Huerta</name>
</author>
<author><name sortKey="Davidovitch, Nadav" sort="Davidovitch, Nadav" uniqKey="Davidovitch N" first="Nadav" last="Davidovitch">Nadav Davidovitch</name>
</author>
<author><name sortKey="Grotto, Itamar" sort="Grotto, Itamar" uniqKey="Grotto I" first="Itamar" last="Grotto">Itamar Grotto</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="ISSN">1080-6040</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (economics)</term>
<term>Acetamides (therapeutic use)</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Antiviral Agents (economics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cost-Benefit Analysis</term>
<term>Disease Outbreaks (economics)</term>
<term>Humans</term>
<term>Infant</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (economics)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Israel (epidemiology)</term>
<term>Middle Aged</term>
<term>Models, Biological</term>
<term>Models, Economic</term>
<term>Oseltamivir</term>
<term>World Health Organization</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Israel</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cost-Benefit Analysis</term>
<term>Humans</term>
<term>Infant</term>
<term>Middle Aged</term>
<term>Models, Biological</term>
<term>Models, Economic</term>
<term>Oseltamivir</term>
<term>World Health Organization</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16102319</PMID>
<DateCompleted><Year>2005</Year>
<Month>10</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-6040</ISSN>
<JournalIssue CitedMedium="Print"><Volume>11</Volume>
<Issue>8</Issue>
<PubDate><Year>2005</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Cost-benefit of stockpiling drugs for influenza pandemic.</ArticleTitle>
<Pagination><MedlinePgn>1280-2</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We analyzed strategies for the use of stockpiled antiviral drugs in the context of a future influenza pandemic and estimated cost-benefit ratios. Current stockpiling of oseltamivir appears to be cost-saving to the economy under several treatment strategies, including therapeutic treatment of patients and postexposure prophylactic treatment of patients' close contacts.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Balicer</LastName>
<ForeName>Ran D</ForeName>
<Initials>RD</Initials>
<AffiliationInfo><Affiliation>Ministry of Health, Jerusalem, Israel. rbalicer@netvision.net.il</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Huerta</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Davidovitch</LastName>
<ForeName>Nadav</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grotto</LastName>
<ForeName>Itamar</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018803" MajorTopicYN="N">Models, Economic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>10</Month>
<Day>12</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16102319</ArticleId>
<ArticleId IdType="pmc">PMC3320484</ArticleId>
<ArticleId IdType="doi">10.3201/eid1108.041156</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2002 Jan;40(1):84-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11773097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2003 Jan;9(1):1-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12691538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2003 Jun 7;326(7401):1235</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12791735</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 2004 Apr 1;159(7):623-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15033640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2004 Apr 1;38(7):925-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034821</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2004 Mar 12;79(11):107-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15114955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2004 Jun 12;328(7453):1391-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15191958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 2004 Apr;82(4):242</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15259251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 2004 Apr;82(4):317-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15309817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Epidemiol. 1984 Mar;13(1):112-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6698695</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1989 Dec 21;321(25):1696-702</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2687687</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1999 Jul 7;282(1):31-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10404908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 1999 Sep-Oct;5(5):659-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10511522</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1999 Oct 28;341(18):1336-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10536125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2005 Mar 5;330(7490):495</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15746113</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Am. 2005 May;292(5):20, 22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15882011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2003 Jul 28;163(14):1667-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885681</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2000 Feb 23;283(8):1016-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10697061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2000 Nov;48(2):101-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11114412</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2001;61(2):263-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11270942</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E42 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E42 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:16102319 |texte= Cost-benefit of stockpiling drugs for influenza pandemic. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16102319" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |